Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(03): 298-303
DOI: 10.1055/s-0042-1745814
Original Article

Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost-Saving Approach—A Survey Report

Amol Patel 
1   Department of Medicine, INHS ASVINI, Mumbai, Maharashtra, India
,
Amol Akhade
2   Topiwala National Medical College and Nair Hospital, Mumbai, Maharashtra, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Use of immunotherapy drugs has increased leaps and bounds in the last decade with promising results in some of the cancers. The use is limited in low- and middle-income countries due to cost constraints. Weight-based dosing is one measure adopted by Canada and Israel to reduce cost burden and improve access to immunotherapeutic drugs.

Objective We conducted a survey among medical oncologists from India to understand challenges faced in accepting the weight-based dosing of pembrolizumab.

Materials and Methods Questionnaire covering various aspects related to use of immunotherapy drugs was made and it was circulated across various social media platforms. Medical oncologists practicing across India were invited to participate in this survey. The issues like access to drugs and awareness about weight-based dosing of pembrolizumab were covered in the survey. Also, the impact of international guidelines on accepting the weigh-based dosing was studied.

Results Ninety-nine medical oncologists across India participated in the survey. Only 60% medical oncologists are aware about weight-based dosing of pembrolizumab practiced in other countries. Further, 70% of medical oncologists could not prescribe immunotherapy due to cost factor in majority (90%) of their patients. More than 90% agreed that they will use weight-based dosing of pembrolizumab if the Drug Controller General of India, National Comprehensive Cancer Network, or European Society of Medical Oncologists guidelines endorses weight-based dosing.

Conclusion Weight-based dosing of pembrolizumab would be accepted if policy makers and Indian medical oncology societies come together and formulate guidelines. Such guidelines will improve accessibility to immunotherapy drugs and lead to huge cost savings.

Keywords

DCGI India - pembrolizumab - survey - weight-based dose


Publication History

Article published online:
20 May 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References:

  • 1 Robert C, Thomas L, Bondarenko I. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364 (26) 2517-2526
    CrossrefPubMedGoogle Scholar
  • 2 Kastor A, Mohanty SK. Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: Do Indian households face distress health financing?. PLoS One 2018; 13 (05) e0196106
    CrossrefPubMedGoogle Scholar
  • 3 Noronha V, Abraham G, Patil V. et al. A real-world data of immune checkpoint inhibitors in solid tumors from India. Cancer Med 2021; 10 (05) 1525-1534
    CrossrefPubMedGoogle Scholar
  • 4 Garon EB, Rizvi NA, Hui R. et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21) 2018-2028
    CrossrefPubMedGoogle Scholar
  • 5 Ribas A, Puzanov I, Dummer R. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16 (08) 908-918
    Google Scholar
  • 6 Herbst RS, Baas P, Kim D-W. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387 (10027): 1540-1550
    CrossrefPubMedGoogle Scholar
  • 7 Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 2019; 58 (07) 835-857
    CrossrefPubMedGoogle Scholar
  • 8 Hafizi D, Eurich D. Canadian Agency for Drugs and Technologies in Health. CADTH technology review: optimal use 360 report: dosing and timing of immuno-oncology drugs. Published online November 2019. Accessed May 19, 2020 https://www.cadth.ca/sites/default/files/ou-tr/ho0008-dosing-timing-immuno-oncology-drugs.pdf
    Google Scholar
  • 9 Goldstein DA, Gordon N, Davidescu M. et al. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Natl Cancer Inst 2017;109(11):
    Google Scholar
  • 10 Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology - when less is more. N Engl J Med 2021; 385 (16) 1445-1447
    CrossrefPubMedGoogle Scholar
  • 11 Prabhash K, Vora A, Limaye S. et al. Treatment of advanced non-small-cell lung cancer: first line, maintenance, and second line–Indian consensus statement update (Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India). Cancer Res Stat Treat 2021; 4 (02) 279-314
    CrossrefGoogle Scholar
  • 12 National Comprehensive Cancer Network guidelines on cutaneous melanoma. Accessed on 2021, Oct 10. Available from https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf
    Google Scholar
  • 13 23rd Expert Committee on Selection and Use of Essential Medicines [Internet]. Accessed March 7, 2022 from: https://www.who.int/news-room/events/detail/2021/06/21/default-calendar/23rd-expert-committee-on-selection-and-use-of-essential-medicines
    Google Scholar
  • 14 Keytruda prescribing information (package insert is based on worldwide physician circular S-CCDS-MK3475- IV-112017)..
    Google Scholar
  • 15 Singh N, Aggarwal AN, Gupta D, Behera D. Prevalence of low body mass index among newly diagnosed lung cancer patients in North India and its association with smoking status. Thorac Cancer 2011; 2 (01) 27-31
    CrossrefPubMedGoogle Scholar
  • 16 Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis 2012; 4 (05) 474-484
    PubMedGoogle Scholar
  • 17 Patnaik A, Kang SP, Rasco D. et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21 (19) 4286-4293
    CrossrefPubMedGoogle Scholar
  • 18 Chatterjee MS, Elassaiss-Schaap J, Lindauer A. et al. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacometrics Syst Pharmacol 2017; 6 (01) 29-39
    CrossrefPubMedGoogle Scholar
  • 19 Chatterjee M, Turner DC, Felip E. et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 2016; 27 (07) 1291-1298
    CrossrefPubMedGoogle Scholar
  • 20 Monirul S, Rigal M, Chouahnia K. et al. Budget impact analysis of fixed dose versus weight-based dosing regimen of nivolumab and pembrolizumab in the treatment of non-small cell lung cancer. Vaccines (Basel) 2020; 8 (04) 730
    CrossrefPubMedGoogle Scholar
  • 21 Hall E, Zhang J, Kim EJ. et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med 2020; 9 (06) 2106-2112
    CrossrefPubMedGoogle Scholar
  • 22 Gamba T, Caglio A, Sacchi F. et al. Impact of different dosing strategies of nivolumab in patients with solid tumors: Italian single center analysis. Ann Oncol Res. 2021; 1 (01) 61
    CrossrefGoogle Scholar